Identification and panoramic analysis of drug response-related genes in triple negative breast cancer using as an example NVP-BEZ235

[1]  A. Boccarelli,et al.  Cluster of resistance-inducing genes in MCF-7 cells by estrogen, insulin, methotrexate and tamoxifen extracted via NMF. , 2023, Pathology, research and practice.

[2]  Zhongxin Lu,et al.  LINC00094/miR-19a-3p/CYP19A1 axis affects the sensitivity of ER positive breast cancer cells to Letrozole through EMT pathway , 2022, Aging.

[3]  Shi-Jin Wang,et al.  CircPVT1 facilitates the progression of oral squamous cell carcinoma by regulating miR-143-3p/SLC7A11 axis through MAPK signaling pathway , 2022, Functional & Integrative Genomics.

[4]  H. Romanowicz,et al.  Breast Cancer—Epidemiology, Classification, Pathogenesis and Treatment (Review of Literature) , 2022, Cancers.

[5]  Jun-ye Wang,et al.  A Novel Inflammatory-Related Gene Signature Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma , 2022, Frontiers in Genetics.

[6]  Lei Wang,et al.  Silencing lncRNA SLC16A1-AS1 Induced Ferroptosis in Renal Cell Carcinoma Through miR-143-3p/SLC7A11 Signaling , 2022, Technology in cancer research & treatment.

[7]  Yuqiao Chen,et al.  An Immune Panel Signature Predicts Prognosis of Lung Adenocarcinoma Patients and Correlates With Immune Microenvironment , 2021, Frontiers in Cell and Developmental Biology.

[8]  Yuhong Li,et al.  Identification and Prognostic Value Exploration of Cyclophosphamide (Cytoxan)-Centered Chemotherapy Response-Associated Genes in Breast Cancer. , 2021, DNA and cell biology.

[9]  G. Di,et al.  A Novel Seven Gene Signature-Based Prognostic Model to Predict Distant Metastasis of Lymph Node-Negative Triple-Negative Breast Cancer , 2021, Frontiers in Oncology.

[10]  Xia Yang,et al.  A combined hypoxia and immune gene signature for predicting survival and risk stratification in triple-negative breast cancer , 2021, Aging.

[11]  Yinsheng Wang,et al.  ATF3 Modulates the Resistance of Breast Cancer Cells to Tamoxifen through an N6-Methyladenosine-Based Epitranscriptomic Mechanism. , 2021, Chemical research in toxicology.

[12]  Jihong Liu,et al.  Integrated Analysis to Identify a Redox-Related Prognostic Signature for Clear Cell Renal Cell Carcinoma , 2021, Oxidative medicine and cellular longevity.

[13]  Xin Hu,et al.  Bulk and Single-cell Transcriptome Profiling Reveal the Metabolic Heterogeneity in Human Breast Cancers. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.

[14]  Lihua Zhang,et al.  Tumor microenvironment characterization in triple-negative breast cancer identifies prognostic gene signature , 2021, Aging.

[15]  James M. McFarland,et al.  Global computational alignment of tumor and cell line transcriptional profiles , 2021, Nature Communications.

[16]  X. Zu,et al.  Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer , 2021, Theranostics.

[17]  A. Dirican,et al.  Atezolizumab in Patients with Metastatic Urothelial Carcinoma Who Have Progressed After First-line Chemotherapy: Results of Real-life Experiences. , 2020, European urology focus.

[18]  Si-ying Zhou,et al.  Identification and validation of prognostic signature for breast cancer based on genes potentially involved in autophagy , 2020, PeerJ.

[19]  Jingwu Jiang,et al.  Identification of a prognosis-associated signature associated with energy metabolism in triple-negative breast cancer , 2020, Oncology reports.

[20]  N. Shao,et al.  lncRNA NR2F1‐AS1 promotes breast cancer angiogenesis through activating IGF‐1/IGF‐1R/ERK pathway , 2020, Journal of cellular and molecular medicine.

[21]  Yankai Xia,et al.  Prognostic value of an autophagy-related gene expression signature for endometrial cancer patients , 2020, Cancer Cell International.

[22]  Q. Ma,et al.  The PI3K/mTOR dual inhibitor NVP‐BEZ235 stimulates mutant p53 degradation to exert anti‐tumor effects on triple‐negative breast cancer cells , 2020, FEBS open bio.

[23]  S. Schnittger,et al.  A phase I study of a dual PI3-kinase/mTOR inhibitor BEZ235 in adult patients with relapsed or refractory acute leukemia , 2020, BMC pharmacology & toxicology.

[24]  G. Guney Eskiler.  The Interaction of PI3K Inhibition with Homologous Recombination Repair in Triple Negative Breast Cancer Cells. , 2019, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[25]  Beibei Ru,et al.  TISIDB: an integrated repository portal for tumor-immune system interactions , 2019, Bioinform..

[26]  Xiaoqing Guan,et al.  MicroRNA-33a-5p overexpression sensitizes triple-negative breast cancer to doxorubicin by inhibiting eIF5A2 and epithelial-mesenchymal transition , 2019, Oncology letters.

[27]  Zhi-zhong Ye,et al.  A predicted risk score based on the expression of 16 autophagy-related genes for multiple myeloma survival , 2019, Oncology letters.

[28]  R. Brem,et al.  Dynamically decreased miR-671-5p expression is associated with oncogenic transformation and radiochemoresistance in breast cancer , 2019, Breast Cancer Research.

[29]  F. Bertucci,et al.  A Tyrosine Kinase Expression Signature Predicts the Post-Operative Clinical Outcome in Triple Negative Breast Cancers , 2019, Cancers.

[30]  L. Xing,et al.  Prognostic 4-lncRNA-based risk model predicts survival time of patients with head and neck squamous cell carcinoma , 2019, Oncology letters.

[31]  John W M Martens,et al.  MicroRNAs as possible indicators of drug sensitivity in breast cancer cell lines , 2019, PloS one.

[32]  Xin Hu,et al.  Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. , 2019, Cancer cell.

[33]  Eytan Ruppin,et al.  Publisher Correction: Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.

[34]  M. Beibel,et al.  TORC1 inhibition enhances immune function and reduces infections in the elderly , 2018, Science Translational Medicine.

[35]  W. Gradishar,et al.  Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review , 2018, Breast Cancer Research and Treatment.

[36]  Jun Ma,et al.  Transcriptome profiling identified differentially expressed genes and pathways associated with tamoxifen resistance in human breast cancer , 2017, Oncotarget.

[37]  Ayesha Obaid,et al.  MicroRNA pharmacogenomics based integrated model of miR-17-92 cluster in sorafenib resistant HCC cells reveals a strategy to forestall drug resistance , 2017, Scientific Reports.

[38]  P. Jutabha,et al.  Increase in L-type amino acid transporter 1 expression during cholangiocarcinogenesis caused by liver fluke infection and its prognostic significance. , 2017, Parasitology international.

[39]  Pornpimol Charoentong,et al.  Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade , 2016, bioRxiv.

[40]  Takashi Suzuki,et al.  CITED2 in breast carcinoma as a potent prognostic predictor associated with proliferation, migration and chemoresistance , 2016, Cancer science.

[41]  J. Machiels,et al.  Phase II study of dual phosphoinositol‐3‐kinase (PI3K) and mammalian target of rapamycin (mTOR) inhibitor BEZ235 in patients with locally advanced or metastatic transitional cell carcinoma , 2016, BJU international.

[42]  Tiefeng Jin,et al.  Superior efficacy of co-treatment with the dual PI3K/mTOR inhibitor BEZ235 and histone deacetylase inhibitor Trichostatin A against NSCLC , 2016, Oncotarget.

[43]  Jong Hoon Park,et al.  miRNAs involved in LY6K and estrogen receptor α contribute to tamoxifen-susceptibility in breast cancer , 2016, Oncotarget.

[44]  Mengmeng Zhang,et al.  Autophagy‐related prognostic signature for breast cancer , 2016, Molecular carcinogenesis.

[45]  J. Mesirov,et al.  The Molecular Signatures Database Hallmark Gene Set Collection , 2015 .

[46]  R. Brem,et al.  miR-671-5p inhibits epithelial-to-mesenchymal transition by downregulating FOXM1 expression in breast cancer , 2015, Oncotarget.

[47]  D. Yee,et al.  Altered regulation of PDK4 expression promotes antiestrogen resistance in human breast cancer cells , 2015, SpringerPlus.

[48]  I. Sohn,et al.  A seven‐gene signature can predict distant recurrence in patients with triple‐negative breast cancers who receive adjuvant chemotherapy following surgery , 2015, International journal of cancer.

[49]  P. Majumder,et al.  Temporally sequenced anticancer drugs overcome adaptive resistance by targeting a vulnerable chemotherapy-induced phenotypic transition , 2015, Nature Communications.

[50]  Paul Geeleher,et al.  pRRophetic: An R Package for Prediction of Clinical Chemotherapeutic Response from Tumor Gene Expression Levels , 2014, PloS one.

[51]  Seung-Woo Hong,et al.  NVP-BEZ235, a dual PI3K/mTOR inhibitor, induces cell death through alternate routes in prostate cancer cells depending on the PTEN genotype , 2014, Apoptosis.

[52]  M. Suresh,et al.  Spontaneous Epithelial-Mesenchymal Transition and Resistance to HER-2-Targeted Therapies in HER-2-Positive Luminal Breast Cancer , 2013, PloS one.

[53]  F. André,et al.  Optimal strategies for the treatment of metastatic triple-negative breast cancer with currently approved agents. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[54]  G. Tseng,et al.  Distinct Genes Related to Drug Response Identified in ER Positive and ER Negative Breast Cancer Cell Lines , 2012, PloS one.

[55]  S. Ramaswamy,et al.  Systematic identification of genomic markers of drug sensitivity in cancer cells , 2012, Nature.

[56]  Adam A. Margolin,et al.  The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.

[57]  Gordon B Mills,et al.  Inhibition of PI3K/mTOR leads to adaptive resistance in matrix-attached cancer cells. , 2012, Cancer cell.

[58]  Erin M. Coffee,et al.  The Dual PI3K/mTOR Inhibitor NVP-BEZ235 Induces Tumor Regression in a Genetically Engineered Mouse Model of PIK3CA Wild-Type Colorectal Cancer , 2011, PloS one.

[59]  N. Ribelles,et al.  Targeted therapy of metastatic breast cancer , 2009, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.

[60]  P. Baumann,et al.  The novel orally bioavailable inhibitor of phosphoinositol-3-kinase and mammalian target of rapamycin, NVP-BEZ235, inhibits growth and proliferation in multiple myeloma. , 2009, Experimental cell research.

[61]  Steve Horvath,et al.  WGCNA: an R package for weighted correlation network analysis , 2008, BMC Bioinformatics.

[62]  C. Sotiriou,et al.  A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancer , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.